Influenza, Human
Conditions
Keywords
Safety, Healthy adults, Immunogenicity, Supra-seasonal universal influenza vaccines - inactivated (SUIVs)
Brief summary
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted) in 18 to 39 year-old healthy subjects. Subjects will be enrolled and vaccinated with one or 2 primary dose(s) followed by a booster dose one year later.
Detailed description
Current seasonal influenza vaccines show good efficacy when they are well-matched with the circulating virus strains. However, influenza viruses constantly change their surface glycoproteins that are the targets of most immune responses, allowing them to escape pre-existing immunity, a process called antigenic drift. Therefore, seasonal influenza vaccines have to be reformulated and re-administered on an annual basis. In addition, novel viruses can appear at irregular intervals and cause influenza virus pandemics that can claim millions of lives. GSK Biologicals is now developing a new influenza vaccine that contains modified inactivated influenza viruses. The purpose of this approach is to elicit an immune response that would protect against all current and future circulating influenza strains without having to administer the vaccine each year.
Interventions
BIOLOGICALD-SUIV cH8/1N1+AS03
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH5/1N1+AS03
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH11/1N1+AS03
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH8/1N1+AS01
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH5/1N1+AS01
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH11/1N1+AS01
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH8/1N1
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH5/1N1
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALD-SUIV cH11/1N1
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALPlacebo
1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
BIOLOGICALFluarix Quadrivalent
1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
The site staff will work in an observer-blind manner. As the vaccines appearance and preparation are different, two teams of study personnel will be set up: * A team of unblinded personnel (responsible for the reception, preparation and administration of the vaccines). * A team of blinded personnel (responsible for the clinical safety evaluation of the subjects).
Eligibility
Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject prior to performance of any study specific procedure. * A male or female between, and including, 18 and 39 years of age at the time of the first vaccination. * Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as established by medical history and clinical examination before first vaccination and laboratory screening tests (the latter being only applicable for subjects enrolled in Phase I). * Subjects with no history of influenza vaccination within 6 months prior to first study vaccination and who are willing to forego any influenza vaccination during the entire study period. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * Has practiced adequate contraception for 30 days prior to first vaccination, and * Has a negative pregnancy test on the day of vaccination, and * Has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series (last vaccination at Month 14).
Exclusion criteria
* Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period. * Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe. * Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed. * Administration of long-acting immune-modifying drugs within 6 months before first vaccination, or planned administration any time during the study period. * Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose up to the blood sampling at Day 85 and in the period starting 30 days before booster vaccination at Month 14 up to the blood sample at Month 14 + 28 days. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. * Previous vaccination against influenza within the 6 months preceding the first vaccination at Visit 1 or planned use of such vaccines during the study period. * History of vaccination with a (pre)pandemic influenza vaccine other than an H1N1pdm09 vaccine or history of laboratory-confirmed influenza infection other than seasonal or H1N1pdm09 influenza. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * History of or current autoimmune disease. * Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling. * History of Guillain-Barré syndrome. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine. * Hypersensitivity to latex. * Acute disease and/or fever at the time of enrolment. * Fever is defined as temperature ≥ 38.0°C / 100.4°F. The preferred location for measuring temperature in this study will be the oral cavity. * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator. * For subjects with acute disease and/or fever at the time of enrolment, Visit 1 may be re-scheduled within the allowed time-window. * Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period. * Blood donation within 30 days before the first study blood sampling or planned blood donation within 30 days before and up to 30 days after any study blood sampling. * Pregnant or lactating female. * History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Female planning to become pregnant or planning to discontinue contraceptive precautions. Additional criterion applicable for Phase I subjects: * Hematological and/or biochemical parameters outside the laboratory normal ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator. * Liver enzymes (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) outside of the normal laboratory ranges.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1 |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | At Day 1 | Anti-H1 stalk immune response measured by MN are expressed in 1/DILUTION (DIL). The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL. |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | At Day 29 | Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL. |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | At Day 85 | Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL. |
| Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | At Day 1 | Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL. |
| Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | At Day 29 | Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay. |
| Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | At Day 85 | Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | Percentage of subjects with an equal or greater than (≥) 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1 |
| MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1 |
| MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | At Day 29, compared to pre-vaccination at Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1 |
| Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | During the 7-day (Days 1-7) follow-up period after first vaccine dose | Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site. |
| Number of Subjects With Solicited Local AEs After Second Dose Administration | During the 7-day (Days 1-7) follow-up period after second vaccine dose | Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site. |
| Number of Subjects With Solicited Local AEs After Booster Dose Administration | During the 7-day (Days 1-7) follow-up period after booster vaccine dose | Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 mm of injection site. |
| Number of Subjects With Solicited General AEs After First Dose Administration | During the 7-day (Days 1-7) follow-up period after first vaccine dose | Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade |
| Number of Subjects With Solicited General AEs After Second Dose Administration | During the 7-day (Days 1-7) follow-up period after second vaccine dose | Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade |
| Number of Subjects With Solicited General AEs After Booster Dose Administration | During the 7-day (Days 1-7) follow-up period after booster vaccine dose | Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. |
| Number of Subjects With Any Unsolicited AEs Post-vaccination Period | During the 28-day (Days 1-28) follow-up period accross doses | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination |
| Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | At Day 8 | Hematological parameters assessed are: Eosinophils increase \[EOSi\], hemoglobin decrease \[HEMd\] , lymphocytes decrease \[LYMd\], Neutrophils decrease \[NEUd\], platelets decrease \[PLTCd\], white blood cells decrease \[WBCd\], WBC increase \[WBCi\]. Biochemical parameters assessed are: alanine aminotransferase increase \[ALTi\], aspartate aminotransferase increase \[ASTi\], blood urea nitrogen \[BUN\], creatinine \[CRE\].Toxicity grading is according to the Food and Drug Administration (FDA) guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as follows: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as follows: Parameter- grading at Baseline- grading at Timing: e.g.: ALT-Grade 0-Grade 1. |
| Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | From Day 8 to Day 29 | Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome. |
| Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | From Day 8 to Day 85 | Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | At Day 85, compared to pre-vaccination at Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | From Day 8 to Month 14 + 28 days | Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome. |
| Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | From Day 8 to Month 26 | Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) | During the entire study period (from Day 1 up to Month 26) | MAEs are defined as events for which the subject receives medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | During the entire study period (from Day 1 up to Month 26) | pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. |
| Number of Subjects With Serious Adverse Events (SAEs). | During the entire study period (from Day 1 up to Month 26) | SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | At Day 1 | Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 ELISA.Unit per milliliter (EL.U/mL). |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | At Day 29 | Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL. |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | At Day 85 | Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL. |
| Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | At Day 1 | Concentrations are presented as Geometric Mean Concentrations (GMCs) and measured by ELISA. ELISA cut-off = 66 EL.U/mL. |
| Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | At Day 29 | Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL. |
| Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | At Day 85 | Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. | Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL. |
| Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. | Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA. |
| MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1 |
| Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26 | Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18). |
| Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26 | Anti-H2 and anti-H18 immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18). |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA . |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA . |
| MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1. |
| Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | At Days 1, 29 and 85 | Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL |
| Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | At Days 1, 29 and 85 | Anti-H1N1 swine influenza and anti-IIV4-H1N1 immune response measured by MN assay. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: cut-off = 20 1/DIL. |
| Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | At Day 29 and Day 85, compared to Day 1 | Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay. |
| Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | At Day 29 and Day 85, compared to Day 1 | Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay. |
| MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | At Day 29 and at Day 85, compared to Day 1 | MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1. |
| Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 28 days post priming dose(s) i.e. at Day 29 for 1 priming dose groups and at Day 85 for 2 priming doses groups | The adjusted GMCs are presented to evaluate the adjuvant effect post-dose 1 and post-dose 2. |
Countries
Belgium, United States
Participant flow
Pre-assignment details
470 subjects were enrolled and randomized in the study, however, while 2 subjects were allocated subjects numbers, they did not receive any vaccine dose.
Participants by arm
| Arm | Count |
|---|---|
| D-SUIV Adjuvanted Group 1 Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 45 |
| D-SUIV Adjuvanted Group 2 Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 46 |
| D-SUIV Adjuvanted Group 3 Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 47 |
| D-SUIV Adjuvanted Group 4 Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 47 |
| D-SUIV Adjuvanted Group 5 Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 48 |
| D-SUIV Adjuvanted Group 6 Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 47 |
| D-SUIV Unadjuvanted Group 1 Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 47 |
| D-SUIV Unadjuvanted Group 2 Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 48 |
| D-SUIV Unadjuvanted Group 3 Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 46 |
| IIV4 Group Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm. | 47 |
| Total | 468 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT | 1 | 0 | 0 | 5 | 3 | 3 | 3 | 3 | 2 | 2 |
| Overall Study | Lost to Follow-up | 10 | 10 | 19 | 12 | 11 | 12 | 21 | 15 | 12 | 14 |
| Overall Study | MIGRATED / MOVED FROM THE STUDY AREA | 0 | 2 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | NOT WILLING TO PARTICIPATE THIS VISIT | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Other | 0 | 4 | 3 | 2 | 2 | 2 | 0 | 0 | 1 | 0 |
| Overall Study | SERIOUS ADVERSE EVENT AND/OR PIMD | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | IIV4 Group | Total | D-SUIV Adjuvanted Group 1 | D-SUIV Adjuvanted Group 2 | D-SUIV Adjuvanted Group 3 | D-SUIV Adjuvanted Group 4 | D-SUIV Adjuvanted Group 5 | D-SUIV Adjuvanted Group 6 | D-SUIV Unadjuvanted Group 1 | D-SUIV Unadjuvanted Group 2 | D-SUIV Unadjuvanted Group 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 29.3 Years STANDARD_DEVIATION 5.8 | 29.0 Years STANDARD_DEVIATION 6 | 29.0 Years STANDARD_DEVIATION 6.6 | 29.3 Years STANDARD_DEVIATION 5.7 | 28.6 Years STANDARD_DEVIATION 6 | 28.7 Years STANDARD_DEVIATION 6.4 | 29.1 Years STANDARD_DEVIATION 6.2 | 28.8 Years STANDARD_DEVIATION 6.1 | 29.6 Years STANDARD_DEVIATION 5.8 | 28.5 Years STANDARD_DEVIATION 5.9 | 28.8 Years STANDARD_DEVIATION 5.9 |
| Race/Ethnicity, Customized American indian or alaska native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - central / south asian heritage | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian - east asian heritage | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - south east asian heritage | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black or african american | 9 Participants | 88 Participants | 11 Participants | 9 Participants | 10 Participants | 8 Participants | 5 Participants | 7 Participants | 10 Participants | 13 Participants | 6 Participants |
| Race/Ethnicity, Customized Native hawaiian or other pacific islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other, Not specified | 1 Participants | 10 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized White - arabic / north african heritage | 2 Participants | 5 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized White - caucasian / european heritage | 35 Participants | 359 Participants | 34 Participants | 34 Participants | 37 Participants | 36 Participants | 40 Participants | 38 Participants | 35 Participants | 33 Participants | 37 Participants |
| Sex: Female, Male Female | 27 Participants | 268 Participants | 26 Participants | 27 Participants | 28 Participants | 28 Participants | 27 Participants | 27 Participants | 27 Participants | 26 Participants | 25 Participants |
| Sex: Female, Male Male | 20 Participants | 200 Participants | 19 Participants | 19 Participants | 19 Participants | 19 Participants | 21 Participants | 20 Participants | 20 Participants | 22 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 45 | 0 / 46 | 0 / 47 | 0 / 47 | 0 / 48 | 1 / 47 | 0 / 47 | 0 / 48 | 0 / 46 | 0 / 47 |
| other Total, other adverse events | 40 / 45 | 43 / 46 | 44 / 47 | 44 / 47 | 45 / 48 | 44 / 47 | 34 / 47 | 38 / 48 | 42 / 46 | 44 / 47 |
| serious Total, serious adverse events | 2 / 45 | 1 / 46 | 1 / 47 | 2 / 47 | 2 / 48 | 2 / 47 | 0 / 47 | 2 / 48 | 2 / 46 | 3 / 47 |
Outcome results
Primary
Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1
Concentrations are presented as Geometric Mean Concentrations (GMCs) and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
Time frame: At Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 8887.9 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 8719.3 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9691 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9121 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9948.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 8555.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9019.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9278.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9039.3 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 | 9160 EL.U/mL |
Primary
Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29
Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
Time frame: At Day 29
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 112973.2 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 45645 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 116596.8 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 61634.2 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 46596.2 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 67114.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 35580.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 20398.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 36426.2 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 | 21938.1 EL.U/mL |
Primary
Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85
Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
Time frame: At Day 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 45351.6 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 28437.5 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 74639.7 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 30419.3 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 25718.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 48775.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 28617.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 15105.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 37911.4 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 | 16749.9 EL.U/mL |
Primary
Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29
MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 12.4 Ratio |
| D-SUIV Adjuvanted Group 2 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 5.9 Ratio |
| D-SUIV Adjuvanted Group 3 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 12.6 Ratio |
| D-SUIV Adjuvanted Group 4 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 6.8 Ratio |
| D-SUIV Adjuvanted Group 5 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 4.7 Ratio |
| D-SUIV Adjuvanted Group 6 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 8.1 Ratio |
| D-SUIV Unadjuvanted Group 1 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 4.2 Ratio |
| D-SUIV Unadjuvanted Group 2 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 2.3 Ratio |
| D-SUIV Unadjuvanted Group 3 | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 3.9 Ratio |
| IIV4 Group | Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 2.4 Ratio |
Primary
MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85
MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 5 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 3.4 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 8.1 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 3.4 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 2.6 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 6.3 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 3.4 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 1.7 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 3.8 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 1.8 Ratio |
Primary
MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29
MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.6 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.3 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 1.9 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 1.7 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 | 2.2 Ratio |
Primary
MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85
MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 1.6 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2.2 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2.5 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 1.1 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2.5 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 1.2 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 1.6 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 | 2.4 Ratio |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29
Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
Time frame: At Day 29
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 41 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 39 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 | 40 Participants |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85
Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
Time frame: At Day 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 36 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 35 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 | 38 Participants |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1
Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 ELISA.Unit per milliliter (EL.U/mL).
Time frame: At Day 1
Population: Analysis of immunogenicity was performed on the Per-Protocol Set (PPS) which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 46 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 48 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 47 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 46 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 44 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 | 45 Participants |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1
Anti-H1 stalk immune response measured by MN are expressed in 1/DILUTION (DIL). The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
Time frame: At Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 32 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 34 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 33 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 40 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 31 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 | 33 Participants |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29
Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
Time frame: At Day 29
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 41 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 41 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 36 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 37 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 | 40 Participants |
Primary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85
Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
Time frame: At Day 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 36 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 38 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 30 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 32 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 35 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 | 37 Participants |
Primary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: During the entire study period (from Day 1 up to Month 26)
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| IIV4 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
Primary
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
MAEs are defined as events for which the subject receives medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: During the entire study period (from Day 1 up to Month 26)
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 21 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 16 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 20 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 23 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 21 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 14 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 19 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 18 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 23 Participants |
| IIV4 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 20 Participants |
Primary
Number of Subjects With Any Unsolicited AEs Post-vaccination Period
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination
Time frame: During the 28-day (Days 1-28) follow-up period accross doses
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 27 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 23 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 23 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 24 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 24 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 17 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 22 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 23 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 22 Participants |
| IIV4 Group | Number of Subjects With Any Unsolicited AEs Post-vaccination Period | 21 Participants |
Primary
Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading
Hematological parameters assessed are: Eosinophils increase \[EOSi\], hemoglobin decrease \[HEMd\] , lymphocytes decrease \[LYMd\], Neutrophils decrease \[NEUd\], platelets decrease \[PLTCd\], white blood cells decrease \[WBCd\], WBC increase \[WBCi\]. Biochemical parameters assessed are: alanine aminotransferase increase \[ALTi\], aspartate aminotransferase increase \[ASTi\], blood urea nitrogen \[BUN\], creatinine \[CRE\].Toxicity grading is according to the Food and Drug Administration (FDA) guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as follows: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as follows: Parameter- grading at Baseline- grading at Timing: e.g.: ALT-Grade 0-Grade 1.
Time frame: At Day 8
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 3, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, GRADE 0, UNKNOWN | 2 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
Primary
Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading
Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
Time frame: From Day 8 to Day 29
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 42 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
Primary
Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading
Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
Time frame: From Day 8 to Day 85
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 7 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
Primary
Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading
Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
Time frame: From Day 8 to Month 14 + 28 days
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 33 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 33 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 7 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 30 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 7 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 13 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 7 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 6 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 36 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 6 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
Primary
Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading
Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: ALT-Grade 0-Grade 1. The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
Time frame: From Day 8 to Month 26
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 33 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 9 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 32 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 31 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 7 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 2 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 39 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 43 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 8 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 47 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 42 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 35 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 41 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 14 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 7 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 45 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 38 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 36 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 3 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 37 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 29 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 1 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 0 | 41 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, GRADE 0 | 46 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 0 | 39 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 3, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 1 | 6 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 1 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 2, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 0 | 34 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | CRE, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 0 | 40 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, UNKNOWN, GRADE 0 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 1, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, GRADE 0 | 43 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 0, GRADE 0 | 42 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 0 | 36 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 0, UNKNOWN | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, UNKNOWN, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, UNKNOWN, GRADE 0 | 2 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 1, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, UNKNOWN, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 1 | 7 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | PLTCd, GRADE 0, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 1 | 4 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 1, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 3, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 0 | 45 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | EOSi, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ALTi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 4 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, UNKNOWN, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCd, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 0, GRADE 1 | 6 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | WBCi, GRADE 0, GRADE 3 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | NEUd, GRADE 2, GRADE 2 | 1 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | LYMd, GRADE 1, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 0, GRADE 2 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | ASTi, GRADE 2, GRADE 0 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | BUN, GRADE 1, GRADE 1 | 0 Participants |
| IIV4 Group | Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading | HEMd, GRADE 2, GRADE 3 | 0 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs).
SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Day 1 up to Month 26)
Population: Analysis was performed on the ES which included all subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Serious Adverse Events (SAEs). | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Serious Adverse Events (SAEs). | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Serious Adverse Events (SAEs). | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Serious Adverse Events (SAEs). | 2 Participants |
| IIV4 Group | Number of Subjects With Serious Adverse Events (SAEs). | 3 Participants |
Primary
Number of Subjects With Solicited General AEs After Booster Dose Administration
Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 7-day (Days 1-7) follow-up period after booster vaccine dose
Population: Analysis was performed on the ES which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 9 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 6 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 15 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 15 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 17 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 19 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 13 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 13 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 8 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 8 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 15 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 8 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 6 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 14 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 17 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 5 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 16 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 15 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 15 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 4 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 16 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 9 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 20 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 14 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 6 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 13 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 15 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 9 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 5 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 10 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 9 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 7 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 4 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 6 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 5 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Shivering | 1 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Temperature | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Fatigue | 3 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Myalgia | 3 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Headache | 4 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Arthralgia | 1 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Booster Dose Administration | Gastrointestinal symptoms | 0 Participants |
Primary
Number of Subjects With Solicited General AEs After First Dose Administration
Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade
Time frame: During the 7-day (Days 1-7) follow-up period after first vaccine dose
Population: Analysis was performed on the ES which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 6 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 18 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 17 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 16 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 6 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 13 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 18 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 18 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 1 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 6 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 7 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 19 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 9 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 10 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 10 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 19 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 22 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 18 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 10 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 17 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 23 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 16 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 21 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 8 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 8 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 19 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 26 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 8 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 18 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 8 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 20 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 9 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 16 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 9 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 6 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 17 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 6 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 5 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 1 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 9 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 19 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 8 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 19 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 10 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 12 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 15 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 6 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Shivering | 3 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Temperature | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Fatigue | 12 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Myalgia | 11 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Headache | 14 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Arthralgia | 5 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After First Dose Administration | Gastrointestinal symptoms | 8 Participants |
Primary
Number of Subjects With Solicited General AEs After Second Dose Administration
Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as oral temperature equal to or above 38.0 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade
Time frame: During the 7-day (Days 1-7) follow-up period after second vaccine dose
Population: Analysis was performed on the ES which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 8 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 3 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 7 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 5 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 3 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 6 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 7 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 12 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 12 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 13 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 10 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 3 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 6 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 7 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 9 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 7 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 3 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 4 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 12 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 4 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 8 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 6 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 16 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 5 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 3 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 5 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 2 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 12 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 5 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 10 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 8 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 2 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 6 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Shivering | 1 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Temperature | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Fatigue | 5 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Myalgia | 3 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Headache | 7 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Arthralgia | 2 Participants |
| IIV4 Group | Number of Subjects With Solicited General AEs After Second Dose Administration | Gastrointestinal symptoms | 2 Participants |
Primary
Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration
Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 1-7) follow-up period after first vaccine dose
Population: Analysis was performed on the Exposed Set (ES) which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 4 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 3 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 2 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 37 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 4 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 2 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 39 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 3 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 16 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 13 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 15 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 1 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 1 Participants |
| IIV4 Group | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Erythema | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Swelling | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration | Pain | 35 Participants |
Primary
Number of Subjects With Solicited Local AEs After Booster Dose Administration
Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 mm of injection site.
Time frame: During the 7-day (Days 1-7) follow-up period after booster vaccine dose
Population: Analysis was performed on the ES which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 2 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 27 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 31 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 26 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 1 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 29 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 28 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 25 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 1 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 10 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 13 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Erythema | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Swelling | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Booster Dose Administration | Pain | 21 Participants |
Primary
Number of Subjects With Solicited Local AEs After Second Dose Administration
Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 1-7) follow-up period after second vaccine dose
Population: Analysis was performed on the ES which included all subjects with the vaccine dose documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 5 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 2 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 4 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 1 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 29 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 2 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 8 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 32 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 2 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 4 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 5 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 12 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Second Dose Administration | Erythema | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Second Dose Administration | Swelling | 0 Participants |
| IIV4 Group | Number of Subjects With Solicited Local AEs After Second Dose Administration | Pain | 10 Participants |
Primary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29
Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 58.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 35 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 61 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 30 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 21.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 42.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 13.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 2.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 15.4 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 2.5 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85
Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 12.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 5.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 47.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 17.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 5.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 25.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 17.6 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 14.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 5.3 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29
Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 7.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 7.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 10.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 5.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 7.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 4.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 8.6 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 2.6 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 2.7 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 2.8 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85
Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 2.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 8.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 15.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 3 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 8.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 8.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 6.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 2.9 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29
Percentage of subjects with an equal or greater than (≥) 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 88.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 60 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 87.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 70 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 52.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 83.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 35.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 24.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 38.5 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 | 15 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85
Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 51.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 44.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 79.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 37.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 20.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 80 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 29.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 8.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 37.1 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 | 7.9 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29
Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 29, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 40.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 39.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 31.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 41 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 36.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 31.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 34.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 26.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 29.7 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 | 36.1 Percentage of subjects |
Primary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85
Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 85, compared to pre-vaccination at Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 29.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 38.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 34.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 15.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 31.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 41.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 21.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 18.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 33.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 | 41.2 Percentage of subjects |
Primary
Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1
Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
Time frame: At Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 40.6 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 45.4 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 45.9 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 45.8 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 41.9 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 45.1 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 44.6 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 43.4 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 42.7 Titer |
| IIV4 Group | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 | 38 Titer |
Primary
Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29
Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
Time frame: At Day 29
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 100.3 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 109.3 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 113.1 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 105.6 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 96.4 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 89.8 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 86.2 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 80 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 74.5 Titer |
| IIV4 Group | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 | 87.2 Titer |
Primary
Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85
Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
Time frame: At Day 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 73 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 98.9 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 122.7 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 59.6 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 87.4 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 109.8 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 55.4 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 75.3 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 88.3 Titer |
| IIV4 Group | Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 | 86.1 Titer |
Secondary
Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA
The adjusted GMCs are presented to evaluate the adjuvant effect post-dose 1 and post-dose 2.
Time frame: 28 days post priming dose(s) i.e. at Day 29 for 1 priming dose groups and at Day 85 for 2 priming doses groups
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| D-SUIV Adjuvanted Group 1 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 112206.4 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 47432.6 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 73945.6 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 61356.7 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 45346.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 50602.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 36159.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 20403.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 36826.9 EL.U/mL |
| IIV4 Group | Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA | 21675.2 EL.U/mL |
Comparison: To evaluate the adjuvant effect of AS03 (Pooling of results at Day 29 of D-SUIV Adjuvant Group 1, at Day 29 of D-SUIV Adjuvant Group 2 and Day 85 of D-SUIV Adjuvant Group 3) on the humoral immune response for anti-H1 stalk antibody by ELISA at Day 29 and Day 85 (i.e. 28 days post-vaccination) when compared to the non-adjuvanted formulations (Pooling of results at Day 29 of D-SUIV Unadjuvanted Group 1, at Day 29 of D-SUIV Unadjuvanted Group 2 and Day 85 of D-SUIV Unadjuvanted Group 3).94.46% CI: [2.06, 2.95]Dunnett's t test
Comparison: To evaluate the adjuvant effect of AS01 (Pooling of results at Day 29 of D-SUIV Adjuvant Group 4, at Day 29 of D-SUIV Adjuvant Group 5 and Day 85 of D-SUIV Adjuvant Group 6) on the humoral immune response for anti-H1 stalk antibody by ELISA at Day 29 and Day 85 (i.e. 28 days post-vaccination) when compared to the non-adjuvanted formulations (Pooling of results at Day 29 of D-SUIV Unadjuvanted Group 1, at Day 29 of D-SUIV Unadjuvanted Group 2 and Day 85 of D-SUIV Unadjuvanted Group 3).94.46% CI: [1.46, 2.1]Dunnett's t test
Secondary
Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA
Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).
Time frame: At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 21754.4 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5848.2 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 111973.1 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 42295.4 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 29904.9 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 36459.1 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 24198.7 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 20136.5 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 4936.1 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 11992.9 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 26663.7 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 13071 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 9039.6 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 19763.3 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 12192 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 10832.8 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5975.5 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 28538 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 10240.6 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 14228.2 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 13472.1 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 18172.7 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 19762.5 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 26567.6 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 4845.1 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 11417.4 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 34266 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 8610.3 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 91778 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 12923.2 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 27000.7 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 11823.4 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 38258.4 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 76909.5 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 60609.1 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 115020.5 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 13068.8 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 20291 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 14078.6 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 18529.9 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 36950 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 27305.6 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 30387.7 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5936.9 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 30670.3 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 6882.1 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 12186.4 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 29403.8 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 9767.9 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 26581.4 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 18259.9 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 17100.4 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 27256.3 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 19456.7 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 15358.6 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5299.3 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 19951 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 10270.7 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 10260.8 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 8820.4 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 15768 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 10503.1 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5968.7 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 59190.1 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 10899.7 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 11445.8 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 30980 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 16519.5 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5368.1 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 32287.4 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 24020.6 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 8370.2 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 81616.2 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 6704 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 27477.2 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 12541.2 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 9973.8 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 12402.4 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 12017.1 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 21416.3 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 15872.3 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 28818 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 19573.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 22917.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5513.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 4651.7 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 19348 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 9308.8 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 24555.6 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 17205.7 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 12753.8 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 10216.5 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 39576.4 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 10695.2 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 58542.1 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 64182.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 23576.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 8526.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 14906.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 15050.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 9988.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 19264.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 10283.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 19172.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 13383.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 30976.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 6042.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 10062.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 14269 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 11742.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 9695.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 4991.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5543.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 10899.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5917.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 29940.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 8762.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 13186.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 8182.1 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 6955.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 7937 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 9640.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 7717.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 12543.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 15780.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 8934.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 12700 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 8229 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 11876.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5399.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 12302.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 15219.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 14152.1 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 14564 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 11617.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 25006.7 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 23570.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 22379.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 33198.1 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 21978.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 12617.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 29437.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 41953 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 6320.1 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 8939.2 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 8178.4 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 9409 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 11753.1 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 8582.5 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 9136.2 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 5681.1 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 7961.8 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 7708.3 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 7764.5 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 10941.3 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 10758.1 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 5512.2 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 7646.4 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 9590.3 EL.U/mL |
| IIV4 Group | Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 11675.5 EL.U/mL |
Secondary
Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26
Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
Time frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26.
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 27648.6 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 22687.1 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 49594 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 27068.3 EL.U/mL |
| D-SUIV Adjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 22850.2 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 29027.2 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 17155.9 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 17662.4 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 36133.6 EL.U/mL |
| D-SUIV Adjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 92885.6 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 37282.2 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 41759.7 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 32635.4 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 38120.3 EL.U/mL |
| D-SUIV Adjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 73078 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 21916.1 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 18915.3 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 36709.7 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 20146.8 EL.U/mL |
| D-SUIV Adjuvanted Group 4 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 18266 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 16645.4 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 27491.3 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 31396.4 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 15092.4 EL.U/mL |
| D-SUIV Adjuvanted Group 5 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 75155.7 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 52026.4 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 25279.1 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 24615 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 29988.8 EL.U/mL |
| D-SUIV Adjuvanted Group 6 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 25059.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 16969.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 18408.1 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 18220.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 19028.4 EL.U/mL |
| D-SUIV Unadjuvanted Group 1 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 22653.6 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 29508.2 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 10820.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 16632.9 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 11024.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 2 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 14269 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 22359.8 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 38364 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 22791.5 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 23145.3 EL.U/mL |
| D-SUIV Unadjuvanted Group 3 | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 21673.7 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 12635.2 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 13142.1 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 12050.6 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 12458.4 EL.U/mL |
| IIV4 Group | Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 17593.3 EL.U/mL |
Secondary
MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay
MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1.
Time frame: At Day 29 and at Day 85, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.4 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.1 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.7 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.5 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.4 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.6 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.7 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.5 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.7 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.5 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.4 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.1 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.1 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 0.9 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.2 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 29 | 1.7 Ratio |
| IIV4 Group | MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay | Day 85 | 1.5 Ratio |
Secondary
MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26
MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
Time frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 3 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 2.7 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 2.9 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 5.3 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 2.5 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 3.7 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 12.6 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 2.3 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 4.9 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 4.7 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 3.7 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 4.7 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 4.6 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 9.5 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 2.6 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 2 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 2.3 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 2.3 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 4.3 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 1.6 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 2.6 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 3.1 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 1.4 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 7.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 7.1 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 3.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 3.2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 4 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 3.3 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 2.2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 2.1 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 2.2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 2.7 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 3.4 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 1.2 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 1.8 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 1.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 1.5 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 2.4 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 4.1 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 2.1 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 2.5 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 2.2 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M20 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M8 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M26 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14 | 1.2 Ratio |
| IIV4 Group | MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 | M14+28 days | 1.7 Ratio |
Secondary
MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA
MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1.
Time frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 3.6 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2.6 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 5.2 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 18.4 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 6.1 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 7 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 3.9 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 4.8 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.5 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 4.1 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.9 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 3.5 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 6.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 5.3 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 5 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 6.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 17.2 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 4.6 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2.9 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 2.2 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 2.1 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 3.2 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 3.5 Ratio |
| D-SUIV Adjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.9 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 4.6 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 3.5 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 9.5 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 6.5 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 14.7 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 4.9 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 5.6 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 5.3 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.7 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 6.2 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 17.3 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 3.1 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 5 Ratio |
| D-SUIV Adjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 3.1 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 3.1 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 4.4 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 3.7 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 3.6 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.1 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 3.3 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 3 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 9.9 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 1.8 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.2 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 5.1 Ratio |
| D-SUIV Adjuvanted Group 4 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.8 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.6 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 1.6 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 4.2 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2.2 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 1.8 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 4.8 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 1.8 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.2 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 12.1 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 4.4 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 4.7 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.4 Ratio |
| D-SUIV Adjuvanted Group 5 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 4.1 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 12.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.8 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.5 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 4.1 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 8.2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 5.2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 3.2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 4.9 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 4.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 12.6 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 4.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 4.3 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 6.2 Ratio |
| D-SUIV Adjuvanted Group 6 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 2.6 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 2.1 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 2.5 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 2.6 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 2.7 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.7 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 2.4 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 5.6 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 4.1 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 3.3 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 2.5 Ratio |
| D-SUIV Unadjuvanted Group 1 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 3.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 2.1 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 5.6 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 1.4 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 2.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 1.6 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 2.3 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 1.4 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 2.7 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 1.7 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 1.6 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 1.5 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 2.4 Ratio |
| D-SUIV Unadjuvanted Group 2 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 1.6 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 3.7 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 4.2 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 5 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 2.8 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.9 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 2.3 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 3.2 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 2.6 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 6.1 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 2.5 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 1.9 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 3.3 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 2.6 Ratio |
| D-SUIV Unadjuvanted Group 3 | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 2.1 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M20 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14+28 days | 1.7 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 29 | 1.9 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M14 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M8 | 1.5 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, Day 85 | 1.6 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M8 | 1.5 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 85 | 1.6 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, Day 29 | 2 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14 | 1.4 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M26 | 1.4 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M20 | 1.3 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H18, M26 | 1.4 Ratio |
| IIV4 Group | MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA | Anti-H2, M14+28 days | 1.9 Ratio |
Secondary
Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay
Anti-H1N1 swine influenza and anti-IIV4-H1N1 immune response measured by MN assay. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: cut-off = 20 1/DIL.
Time frame: At Days 1, 29 and 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 40 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 36 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 39 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 43 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 38 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 41 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 38 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 44 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 37 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 40 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 43 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 32 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 36 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 42 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 35 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 1 | 43 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 85 | 37 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay | Day 29 | 40 Participants |
Secondary
Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26
Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
Time frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26.
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 29 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 29 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 28 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 35 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 29 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 32 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 31 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 30 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 26 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 22 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 30 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 24 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 23 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 24 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 27 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 21 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 26 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 25 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 25 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 33 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 31 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 27 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 30 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 22 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 25 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 34 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 26 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 33 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M26 | 23 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M8 | 34 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M20 | 25 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14 | 31 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 | M14+28 days | 29 Participants |
Secondary
Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA
Anti-H2 and anti-H18 immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).
Time frame: At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 45 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 28 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 35 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 29 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 29 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 45 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 43 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 39 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 35 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 28 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 29 Participants |
| D-SUIV Adjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 29 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 30 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 36 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 36 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 32 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 46 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 31 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 31 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 29 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 29 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 32 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 34 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 30 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 24 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 23 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 24 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 23 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 26 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 30 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 30 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 34 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 41 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 46 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 22 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 22 Participants |
| D-SUIV Adjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 26 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 27 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 26 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 25 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 24 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 21 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 27 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 21 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 26 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 25 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 24 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 4 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 40 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 48 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 25 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 48 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 36 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 31 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 25 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 39 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 5 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 29 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 27 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 25 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 35 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 42 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 31 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 27 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 47 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 33 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 25 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 31 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 33 Participants |
| D-SUIV Adjuvanted Group 6 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 47 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 47 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 30 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 37 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 30 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 25 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 22 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 20 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 22 Participants |
| D-SUIV Unadjuvanted Group 1 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 25 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 26 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 34 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 26 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 41 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 34 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 46 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 2 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 34 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 44 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 33 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 33 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 25 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 30 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 27 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 39 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 35 Participants |
| D-SUIV Unadjuvanted Group 3 | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 44 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M8 | 34 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14 | 31 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 29 | 40 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M20 | 25 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 1 | 45 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M8 | 34 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 29 | 40 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M20 | 25 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M26 | 23 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M14+28 days | 29 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, Day 85 | 38 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14+28 days | 29 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 85 | 38 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, M26 | 23 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H2, Day 1 | 45 Participants |
| IIV4 Group | Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA | Anti-H18, M14 | 31 Participants |
Secondary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay
Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 29 and Day 85, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 2.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 2.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 2.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 3 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 2.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26.
Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 10.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 3.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 7.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 17.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 5.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 13.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 3.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 58.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 26.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 30.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 4.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 23.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 16.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 52.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 8.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 7.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 4.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 3.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 24 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 3.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 4 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 9.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 37.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 34.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 9.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 3.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 11.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 12 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 4.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 11.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 3.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 9.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 18.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 12 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 0 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA
Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .
Time frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 14.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 17.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 13.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 6.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 15.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 23.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 25 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 13.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 6.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 2.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 25.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 7.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 67.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 71 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 13.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 10.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 5.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 13.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 25.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 15 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 15 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 2.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 23.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 12 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 68.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 23.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 55.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 6.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 25 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 4.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 25 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 65.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 24.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 18.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 26.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 18.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 4.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 3.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 12.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 24 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 9.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 20.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 11.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 22.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 5.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 3.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 11.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 42.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 4.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 12 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 4.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 16.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 2.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 48.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 25.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 24 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 16.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 2.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 17.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 6.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 8 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 16.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 6.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 12 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 22.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 65.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 5.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 48.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 3.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 61.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 0 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 3 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 12.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 4.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 16.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 8.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 18.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 6.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 9.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 20.6 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 7.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 2.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 15.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 7.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 3.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 2.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 9.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 17.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 7.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 11.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 22.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 20.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 12 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 15.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 10 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 2.5 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 3.4 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 5.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 5.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 2.5 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 0 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay
Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.
Time frame: At Day 29 and Day 85, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 9.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 5.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 22.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 16.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 7.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 18.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 23.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 5.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 21.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 24.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 14.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 9.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 5.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 10.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 2.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 0 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 7.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 8.6 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 29 | 15 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay | Day 85 | 15.8 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26.
Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
Time frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 27.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 20.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 23.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 46.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 20 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 41.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 25 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 83.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 23.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 60 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 50 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 36.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 53.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 50 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 82.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 33.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 14.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 28.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 30.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 44 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 9.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 32 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 38.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 5.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 69 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 75.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 39.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 38.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 48.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 36 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 12 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 20 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 15 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 23.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 22.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 38.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 3.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 8.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 21.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 33.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 13.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 25.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 24 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M20 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M26 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. | M14+28 days | 10.3 Percentage of subjects |
Secondary
Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA
Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .
Time frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 8.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 35.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 41.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 20.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 51.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 55.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 57.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 41.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 24.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 12.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 66.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 17.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 95.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 34.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 52.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 62.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 31 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 36.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 40 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 23.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 71 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 15.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 21.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 20.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 100 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 62.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 33.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 70 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 36 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 92.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 61.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 79.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 44.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 50 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 28.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 75 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 100 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 48.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 54.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 73.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 54.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 30.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 11.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 52 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 45.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 40 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 41.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 30.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 14.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 11.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 29.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 38.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 82.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 20.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 36 Percentage of subjects |
| D-SUIV Adjuvanted Group 4 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 23.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 6.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 57.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 17.9 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 8.3 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 82.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 54.8 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 48 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 45.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 20.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 11.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 6.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 55.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 19.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 5 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 20 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 52.4 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 69.7 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 29 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 56 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 74.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 96.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 29.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 48.6 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 77.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 55.2 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 90.5 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 58.1 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 12 Percentage of subjects |
| D-SUIV Adjuvanted Group 6 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 39.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 18.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 16 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 26.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 14.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 21.6 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 10 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 20 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 20 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 62.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 16.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 36.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 1 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 35.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 18.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 19.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 50 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 5.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 3.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 11.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 5.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 3.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 15.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 2.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 7.4 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 26.8 Percentage of subjects |
| D-SUIV Unadjuvanted Group 2 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 16 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 24.2 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 42.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 23.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 20.5 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 25.9 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 25.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 12 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 63 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 11.1 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 48.7 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 32 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 33.3 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 37 Percentage of subjects |
| D-SUIV Unadjuvanted Group 3 | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 13.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M26 | 4.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 29 | 15 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M20 | 4 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M8 | 0 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M14+28 days | 6.9 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M14+28 days | 6.9 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, Day 85 | 5.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 85 | 5.3 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, Day 29 | 12.5 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H2, M20 | 4 Percentage of subjects |
| IIV4 Group | Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA | Anti-H18, M26 | 0 Percentage of subjects |
Secondary
Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay
Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL
Time frame: At Days 1, 29 and 85
Population: Analysis of immunogenicity was performed on the PPS which included all eligible subjects according to protocol and for whom immunogenicity results were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| D-SUIV Adjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 58.8 Titer |
| D-SUIV Adjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 65.8 Titer |
| D-SUIV Adjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 84 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 93.5 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 89.8 Titer |
| D-SUIV Adjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 61 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 96.1 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 62.9 Titer |
| D-SUIV Adjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 87.2 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 56 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 51.7 Titer |
| D-SUIV Adjuvanted Group 4 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 84.3 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 53.7 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 93.1 Titer |
| D-SUIV Adjuvanted Group 5 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 81.5 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 80 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 56.2 Titer |
| D-SUIV Adjuvanted Group 6 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 86.6 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 56.2 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 63.9 Titer |
| D-SUIV Unadjuvanted Group 1 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 71.5 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 78.7 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 70.9 Titer |
| D-SUIV Unadjuvanted Group 2 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 68 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 69.4 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 56.6 Titer |
| D-SUIV Unadjuvanted Group 3 | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 84.9 Titer |
| IIV4 Group | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 1 | 60.6 Titer |
| IIV4 Group | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 85 | 99.6 Titer |
| IIV4 Group | Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay | Day 29 | 103.7 Titer |